Published • loading... • Updated
Barclays Raises Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $35.00
Summary by thecerbatgem.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Barclays Raises Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $35.00
Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Free Report) had its price target lifted by Barclays from $32.00 to $35.00 in a research report issued on Monday, Benzinga reports. The brokerage presently has an “overweight” rating on the biopharmaceutical company’s stock. Barclays‘s target price suggests a potential upside of 124.22% from the company’s current price. RARE has […]
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
